These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 24684645)
1. Budget impact analysis of antiepileptic drugs for Lennox-Gastaut syndrome. Skornicki M; Clements KM; O'Sullivan AK J Manag Care Spec Pharm; 2014 Apr; 20(4):400-6. PubMed ID: 24684645 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of antiepileptic drugs in the treatment of Lennox-Gastaut syndrome. Clements KM; Skornicki M; O'Sullivan AK Epilepsy Behav; 2013 Oct; 29(1):184-9. PubMed ID: 23973644 [TBL] [Abstract][Full Text] [Related]
3. Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years. Conry JA; Ng YT; Kernitsky L; Mitchell WG; Veidemanis R; Drummond R; Isojarvi J; Lee D; Paolicchi JM; Epilepsia; 2014 Apr; 55(4):558-67. PubMed ID: 24580023 [TBL] [Abstract][Full Text] [Related]
4. Clobazam is efficacious for patients across the spectrum of disease severity of Lennox-Gastaut syndrome: post hoc analyses of clinical trial results by baseline seizure-frequency quartiles and VNS experience. Wheless JW; Isojarvi J; Lee D; Drummond R; Benbadis SR Epilepsy Behav; 2014 Dec; 41():47-52. PubMed ID: 25282105 [TBL] [Abstract][Full Text] [Related]
5. Anti-seizure medications for Lennox-Gastaut syndrome. Brigo F; Jones K; Eltze C; Matricardi S Cochrane Database Syst Rev; 2021 Apr; 4(4):CD003277. PubMed ID: 33825230 [TBL] [Abstract][Full Text] [Related]
6. Indirect comparison of clobazam and other therapies for Lennox-Gastaut syndrome. Cramer JA; Sapin C; François C Acta Neurol Scand; 2013 Aug; 128(2):91-9. PubMed ID: 23410109 [TBL] [Abstract][Full Text] [Related]
7. The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK. Benedict A; Verdian L; Maclaine G Pharmacoeconomics; 2010; 28(3):185-99. PubMed ID: 20151724 [TBL] [Abstract][Full Text] [Related]
8. Use and cost comparison of clobazam to other antiepileptic drugs for treatment of Lennox-Gastaut syndrome. François C; Stern JM; Ogbonnaya A; Lokhandwala T; Landsman-Blumberg P; Duhig A; Shen V; Tan R J Mark Access Health Policy; 2017; 5(1):1318691. PubMed ID: 28740620 [No Abstract] [Full Text] [Related]
10. Rufinamide: a pharmacoeconomic profile of its use as adjunctive therapy in Lennox-Gastaut syndrome. McCormack PL Pharmacoeconomics; 2012 Mar; 30(3):247-56. PubMed ID: 22332960 [TBL] [Abstract][Full Text] [Related]
11. Burden of illness in patients with possible Lennox-Gastaut syndrome: A retrospective claims-based study. Reaven NL; Funk SE; Montouris GD; Saurer TB; Story TJ Epilepsy Behav; 2018 Nov; 88():66-73. PubMed ID: 30241056 [TBL] [Abstract][Full Text] [Related]
12. Deconstructing tolerance with clobazam: Post hoc analyses from an open-label extension study. Gidal BE; Wechsler RT; Sankar R; Montouris GD; White HS; Cloyd JC; Kane MC; Peng G; Tworek DM; Shen V; Isojarvi J Neurology; 2016 Oct; 87(17):1806-1812. PubMed ID: 27683846 [TBL] [Abstract][Full Text] [Related]
13. Expert opinion: Proposed diagnostic and treatment algorithms for Lennox-Gastaut syndrome in adult patients. Montouris G; Aboumatar S; Burdette D; Kothare S; Kuzniecky R; Rosenfeld W; Chung S Epilepsy Behav; 2020 Sep; 110():107146. PubMed ID: 32563898 [TBL] [Abstract][Full Text] [Related]
14. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Ng YT; Conry JA; Drummond R; Stolle J; Weinberg MA; Neurology; 2011 Oct; 77(15):1473-81. PubMed ID: 21956725 [TBL] [Abstract][Full Text] [Related]
15. Current and emerging pharmacotherapy for the treatment of Lennox-Gastaut syndrome. Besag FMC; Vasey MJ; Chin RFM Expert Opin Pharmacother; 2023; 24(11):1249-1268. PubMed ID: 37212330 [TBL] [Abstract][Full Text] [Related]
16. Clobazam and Aggression-Related Adverse Events in Pediatric Patients With Lennox-Gastaut Syndrome. Paolicchi JM; Ross G; Lee D; Drummond R; Isojarvi J Pediatr Neurol; 2015 Oct; 53(4):338-42. PubMed ID: 26245776 [TBL] [Abstract][Full Text] [Related]
17. Clobazam-treated patients with Lennox-Gastaut syndrome experienced fewer seizure-related injuries than placebo patients during trial OV-1012. Isojarvi J; Lee D; Peng G; Sperling MR Epilepsia; 2016 Jun; 57(6):e113-6. PubMed ID: 27145465 [TBL] [Abstract][Full Text] [Related]
18. Clobazam is equally safe and efficacious for seizures associated with Lennox-Gastaut syndrome across different age groups: Post hoc analyses of short- and long-term clinical trial results. Ng YT; Conry J; Mitchell WG; Buchhalter J; Isojarvi J; Lee D; Drummond R; Chung S Epilepsy Behav; 2015 May; 46():221-6. PubMed ID: 25940107 [TBL] [Abstract][Full Text] [Related]
19. Rufinamide for the treatment of Lennox-Gastaut syndrome: evidence from clinical trials and clinical practice. Striano P; McMurray R; Santamarina E; Falip M Epileptic Disord; 2018 Feb; 20(1):13-29. PubMed ID: 29313492 [TBL] [Abstract][Full Text] [Related]
20. Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam use in patients with Lennox-Gastaut syndrome or Dravet syndrome. Nabbout R; Arzimanoglou A; Auvin S; Berquin P; Desurkar A; Fuller D; Nortvedt C; Pulitano P; Rosati A; Soto V; Villanueva V; Cross JH Seizure; 2023 Aug; 110():78-85. PubMed ID: 37331197 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]